Harting Julie, Fernandez Francisco, Kelley Rob, Wiemken Tim, Peyrani Paula, Ramirez Julio
Sullivan University College of Pharmacy, Louisville, KY; Division of Infectious Diseases, University of Louisville School of Medicine, University Hospital, Louisville, KY.
Division of Infectious Diseases, University of Louisville School of Medicine, University Hospital, Louisville, KY.
Diagn Microbiol Infect Dis. 2017 Dec;89(4):294-299. doi: 10.1016/j.diagmicrobio.2017.09.004. Epub 2017 Sep 18.
This retrospective, case series describes our experience with the use of telavancin in patients with methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis and prosthetic joint infection. The primary objectives were clinical outcomes and adverse events (AEs), and a secondary outcome described microbiological susceptibility. Fourteen patients were enrolled. Median duration of therapy was 58 days, and four patients had concurrent bacteremia. End-of-treatment outcomes were available in 78% of patients, with a clinical success rate of 91%. Thirty-day and 12-month outcomes were also obtained. Seven patients experienced AEs. Infusion-related reactions were most common, and three AEs required discontinuation of therapy. All MRSA isolates had a telavancin MIC ≤0.06μg/ml, which is susceptible. This study indicates that telavancin may have a role in treatment of MRSA osteomyelitis and prosthetic joint infection. Our study describes clinical success and adverse events for long duration of therapy, up to 8 weeks.
本回顾性病例系列描述了我们使用替考拉宁治疗耐甲氧西林金黄色葡萄球菌（MRSA）骨髓炎和人工关节感染患者的经验。主要目标是临床结局和不良事件（AE），次要结局描述了微生物敏感性。共纳入14例患者。中位治疗持续时间为58天，4例患者并发菌血症。78%的患者获得了治疗结束时的结局，临床成功率为91%。还获得了30天和12个月的结局。7例患者发生不良事件。与输注相关的反应最为常见，3例不良事件需要停药。所有MRSA分离株的替考拉宁MIC≤0.06μg/ml，属于敏感。本研究表明，替考拉宁可能在MRSA骨髓炎和人工关节感染的治疗中发挥作用。我们的研究描述了长达8周的长期治疗的临床成功和不良事件。
